SIERRA ONCOLOGY

SRRA NASDAQ
0.5021
-0.0326
-6.10%
交易中 11:54 07/23 EDT
开盘
0.5320
昨收
0.5347
最高
0.5320
最低
0.5000
成交量
37.34万
成交均量(3M)
110.42万
52周最高
3.020
52周最低
0.5000
换手率
0.71%
市值
2,633.72万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供SIERRA ONCOLOGY SRRA股票价格,SIERRA ONCOLOGY股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Sierra Oncology, Inc., formerly ProNAi Therapeutics, Inc., is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network. SRA737 is being investigated in approximately two Phase I clinical trials in patients with advanced cancer. Sierra Oncology is also advancing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase (Cdc7) kinase undergoing preclinical development. Sierra is building a range of pipeline of various oncology assets against targets at the edge of cancer biology. The Company’s SRA737 and SRA141 target the DDR network, a scientifically approach with far-reaching potential across oncology. SRA141 is an orally available small molecule inhibitor of Cdc7.
展开 >

最近浏览

名称
价格
涨跌幅